To elucidate novel mechanisms and therapeutic strategies to overcome EGFR/HER2 therapy resistance, we created syngenic SKBR3 human breast cancer cell variants resistant to gefitinib (anti-EGFR) or lapatinib (anti-EGFR/HER2). The gene discussed is EGFR; the disease is breast carcinoma.